Unknown PHASE2 INTERVENTIONAL 2-arm NCT04983550

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

A Multicenter, Randomized, Controlled, Open-label, Phase II Study to Evaluate the Efficacy and Safety of SG001 in Combination With PLD in Patients With Platinum-resistant Relapsed Epithelial Ovarian Cancer

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Epithelial Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer

Interventions Doxorubicin hydrochloride liposome injection SG001

Updated 4 times since 2021 Last updated: Jul 20, 2021 Started: Sep 30, 2021 Primary completion: Jan 31, 2023 Completion: Jan 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Epithelial Ovarian Cancer and Fallopian Tube Cancer, this trial is ongoing. The trial is conducted by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Sep 2021 — Feb 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.